The thromboprotective effect of bortezomib is dependent on the transcription factor Kruppel-like factor 2 (KLF2).

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Blood

• Publication date

  2014-06-12

• Fields of study

  Medicine

• Identifiers
  DOI 10.1182/blood-2014-01-547448PMID 24771858PMCID PMC4055929
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Kruppel-like factor 2 protects against ischemic stroke by regulating endothelial blood brain barrier function.

  2013cited by this paper
• Kruppel-like factor 2 is a transcriptional regulator of chronic and acute inflammation.

  2013cited by this paper
• Endothelial Kruppel-like factor 4 protects against atherothrombosis in mice.

  2012cited by this paper
• Coagulation profiles and thromboembolic events of bortezomib plus thalidomide and dexamethasone therapy in newly diagnosed multiple myeloma.

  2011cited by this paper
• The myeloid transcription factor KLF2 regulates the host response to polymicrobial infection and endotoxic shock.

  2011cited by this paper
• Combination Treatment With VELCADE and Low-Dose Tissue Plasminogen Activator Provides Potent Neuroprotection in Aged Rats After Embolic Focal Ischemia

  2010cited by this paper
• Mammalian Krüppel-like factors in health and diseases.

  2010cited by this paper
• Proteasome Inhibitors Enhance Endothelial Thrombomodulin Expression via Induction of Krüppel-Like Transcription Factors

  2009cited by this paper
• Assessing risk of venous thromboembolism in the patient with cancer.

  2009cited by this paper
• Extended follow‐up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myeloma

  2009cited by this paper
• Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study.

  2009cited by this paper
• Hemostatic effects of bortezomib treatment in patients with relapsed or refractory multiple myeloma

  2008cited by this paper
• Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma.

  2008cited by this paper
• Platelet-monocyte interactions--a dangerous liaison linking thrombosis, inflammation and atherosclerosis.

  2008cited by this paper
• Effects of bortezomib on platelet aggregation and ATP release in human platelets, in vitro.

  2008cited by this paper
• Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer.

  2006cited by this paper
• Kruppel-Like Factor 2 Inhibits Protease Activated Receptor-1 Expression and Thrombin-Mediated Endothelial Activation

  2006cited by this paper
• Morbidity or mortality outcomes associated with prophylactic salpingo-oophorectomy.

  2006cited by this paper
• KLF2 provokes a gene expression pattern that establishes functional quiescent differentiation of the endothelium.

  2006cited by this paper
• Kruppel-like factor 2 (KLF2) regulates proinflammatory activation of monocytes.

  2006cited by this paper
• Kruppel-Like Factor 2 (KLF2) Regulates Endothelial Thrombotic Function

  2005cited by this paper
• Treatment of embolic stroke in rats with bortezomib and recombinant human tissue plasminogen activator

  2005cited by this paper
• Proteasome inhibitor prevents experimental arterial thrombosis in renovascular hypertensive rats

  2004cited by this paper
• The Preparation and Characterization of Novel Peptide Antagonists to Thrombin and Factor VIIa and Activation of Protease-Activated Receptor 1

  2004cited by this paper
• KLF2 Is a Novel Transcriptional Regulator of Endothelial Proinflammatory Activation

  2004cited by this paper
• LKLF: A transcriptional regulator of single-positive T cell quiescence and survival.

  1997cited by this paper

• A novel mechanism in regulating drug sensitivity, growth, and apoptosis of bortezomib-resistant multiple myeloma cells: the USP4/KLF2/HMGA2 cascade

  2025cites this paper
• Stromal and Endothelial Transcriptional Changes during Progression from MGUS to Myeloma and after Treatment Response

  2025cites this paper
• Krüppel-like Factor 2 is an endo-protective transcription factor in diabetic kidney disease.

  2024cites this paper
• Targeting Krüppel-Like Factor 2 as a Novel Therapy for Glomerular Endothelial Cell Injury in Diabetic Kidney Disease

  2024cites this paper
• Thromboembolic risk of carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for newly diagnosed multiple myeloma: A comparative systematic review and meta‐analysis

  2024cites this paper
• The Proteasome Inhibitor Carfilzomib exerts anti-inflammatory and anti-thrombotic effects on the endothelium.

  2024cites this paper
• Endothelial mechanobiology in atherosclerosis.

  2023cites this paper
• A targetable pathway in neutrophils mitigates both arterial and venous thrombosis

  2022cites this paper
• Cardiac macrophages regulate isoproterenol-induced Takotsubo-like cardiomyopathy

  2022cites this paper
• Circadian Rhythm: Potential Therapeutic Target for Atherosclerosis and Thrombosis

  2021cites this paper
• The zinc finger transcription factor, KLF2, protects against COVID-19 associated endothelial dysfunction

  2021cites this paper
• ZMPSTE24 Regulates SARS-CoV-2 Spike Protein–enhanced Expression of Endothelial PAI-1

  2021cites this paper
• Evolutionary Protection of Krüppel-Like Factors 2 and 4 in the Development of the Mature Hemovascular System

  2021cites this paper
• KLF2 is a therapeutic target for COVID-19 induced endothelial dysfunction

  2021cites this paper
• MEF2 (Myocyte Enhancer Factor 2) Is Essential for Endothelial Homeostasis and the Atheroprotective Gene Expression Program.

  2021cites this paper
• The EGFL7-ITGB3-KLF2 axis enhances survival of multiple myeloma in preclinical models.

  2020cites this paper
• THROMBOPROPHYLAXIS IN MULTIPLE MYELOMA PATIENTS RECEIVING IMMUNOMODULATORY DRUGS

  2020cites this paper
• Interacting hepatic PAI-1/tPA gene regulatory pathways influence impaired fibrinolysis severity in obesity

  2020cites this paper
• Thrombosis in hematological malignancies: mechanisms and implications.

  2020cites this paper
• The thromboprotective effect of traditional Chinese medicine Tongji 2 granules is dependent on anti-inflammatory activity by suppression of NF-κB pathways

  2020cites this paper
• Krüppel-like transcription factors in vascular biology and cerebrovascular diseases

  2019influential citation
• Cardiovascular Complications Associated with Multiple Myeloma Therapies: Incidence, Pathophysiology, and Management

  2019cites this paper
• An ATF6-tPA pathway in hepatocytes contributes to systemic fibrinolysis and is repressed by DACH1.

  2019cites this paper
• New Trends in Vascular Inflammation Research: From Biology to Therapy

  2019cites this paper
• Yiqi-Huoxue Granule (YQHX) Downregulates Prothrombotic Factors by Modulating KLF2 and NF-κB in HUVECs following LPS Stimulation

  2019cites this paper
• Uric acid treatment after stroke modulates the Krüppel-like factor 2-VEGF-A axis to protect brain endothelial cell functions: Impact of hypertension.

  2019cites this paper
• Uric acid therapy for vasculoprotection in acute ischemic stroke

  2019cites this paper
• The transcription factor ERG regulates a low shear stress-induced anti-thrombotic pathway in the microvasculature

  2019cites this paper
• Krüppel-Like Factors in Vascular Inflammation: Mechanistic Insights and Therapeutic Potential

  2018influential citation
• Arterial thrombosis and cancer.

  2018cites this paper
• Venous thromboembolism in multiple myeloma – choice of prophylaxis, role of direct oral anticoagulants and special considerations

  2018cites this paper
• Cardiovascular adverse events in multiple myeloma patients.

  2018cites this paper
• Cardiovascular and Thrombotic Complications of Novel Multiple Myeloma Therapies: A Review

  2017cites this paper
• Cardiovascular complications of multiple myeloma in the elderly

  2017cites this paper
• Krüppel-like factors and vascular wall homeostasis

  2017cites this paper
• Krüppel-like factors in endothelial cell biology

  2017cites this paper
• Molecular mechanisms for vascular complications of targeted cancer therapies.

  2016cites this paper
• Cardiovascular Complications of Novel Multiple Myeloma Treatments

  2016cites this paper
• HIV vasculopathy: role of mononuclear cell-associated Krüppel-like factors 2 and 4

  2015cites this paper
• Thrombosis in Lymphoma Patients and in Myeloma Patients.

  2015cites this paper
• Approach to chemotherapy-associated thrombosis

  2015cites this paper
• Study of the thrombogenicity induced by the cytotoxic treatment of malignant disease

  2014cites this paper